evipedia.ai
← Back

Thylakoids for Health & Longevity

Evidence Review created on 08/01/2026 using AI4L / Opus 4.8

Also known as: Thylakoid Membranes, Green Plant Membranes, Chloroplast Thylakoid Membranes, Spinach Thylakoid Extract, Appethyl

Motivation

Thylakoids are the tiny green membranes inside the chloroplasts of plants — the microscopic solar panels where photosynthesis happens. Concentrated from green leaves, most often spinach, and dried into a powder, they become a food-derived supplement taken before meals. Interest centers on a simple observation: swallowing these membranes appears to slow fat digestion, which shifts the gut hormones that signal the brain to stop eating. Early studies report less hunger, fewer cravings, and, in some trials, modest weight loss.

The idea grew out of Swedish laboratory work in the 2000s showing that plant membranes slow the enzyme that breaks down fat. Because appetite, body fat, and blood sugar handling sit near the center of long-term metabolic health, a natural tool for curbing overeating appeals to those focused on healthy aging rather than short-term dieting. At the same time, the supplement has faced scrutiny, and a European regulatory review declined to endorse a weight-loss claim.

This review examines what thylakoids are, how they are proposed to work, and what the human and animal evidence shows about their benefits, risks, and practical use — including where it is thin, conflicting, or shaped by the interests of those who developed the product.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews and expert commentary that introduce thylakoids and the research behind their appetite-related effects.

Note: Of the prioritized experts, substantive thylakoid content was found only from Rhonda Patrick (FoundMyFitness) and Life Extension Magazine. Direct searches of Peter Attia’s, Andrew Huberman’s, and Chris Kresser’s platforms did not return content discussing thylakoids by name, so no items from those sources are included.

Grokipedia

  • Thylakoid

    Grokipedia’s dedicated article covers the biology of thylakoid membranes and their role in photosynthesis, providing structural and biochemical background that underpins the supplement’s proposed mechanism. It is a useful reference for understanding what these membranes are before considering their dietary use.

Examine

  • Thylakoids

    Examine’s dedicated page for thylakoids summarizes what these plant membranes are and maintains a continuously updated research feed of the human and animal studies on their appetite and metabolic effects. It is a useful, independent evidence tracker for readers who want to follow the primary literature on thylakoids as it develops.

ConsumerLab

No dedicated ConsumerLab.com article or product review exists for thylakoids or spinach thylakoid extract as of the creation date.

Systematic Reviews

The following systematic reviews and meta-analyses evaluate the pooled human evidence for thylakoid supplementation on appetite and weight.

Mechanism of Action

The primary proposed mechanism is the slowing of fat digestion in the small intestine. Thylakoid membranes bind to and inhibit the activity of pancreatic lipase and its helper protein colipase (the enzyme system that breaks dietary fat into absorbable pieces). By coating fat droplets and interfering with this enzyme, thylakoids delay — but do not fully block — fat breakdown.

Because fat is digested more slowly, undigested fat travels further down the small intestine to the lower segment (the ileum) before it is absorbed. Fat arriving in this lower region triggers a feedback loop known as the “ileal brake,” which slows stomach emptying and stimulates the release of satiety hormones. Specifically, thylakoids raise cholecystokinin (CCK — a gut hormone that signals fullness) and glucagon-like peptide-1 (GLP-1 — a gut hormone that slows digestion and promotes fullness), while lowering ghrelin (the main hunger-signaling hormone). The net effect is greater and longer-lasting fullness after a meal and reduced drive to eat, including reduced “hedonic hunger” — the craving for palatable, sweet, or fatty foods that is separate from true energy need.

Two additional mechanisms have been proposed. Animal work suggests thylakoids may favorably shift the gut microbiota (the community of gut bacteria) and may bind dietary fat to make a small fraction less available for absorption. A competing, more skeptical interpretation holds that the appetite hormone changes are modest and inconsistent across studies, and that any weight effect is small and largely explained by the mild reduction in fat absorption rather than a robust hormonal “switch.” Both readings are represented in the literature.

Thylakoids are a multi-component biological membrane (proteins, pigments such as chlorophyll and carotenoids, and lipids) that act locally in the gut lumen rather than a single absorbed pharmacological compound; consequently, classical pharmacokinetic properties such as systemic half-life, receptor selectivity, tissue distribution, and hepatic enzyme metabolism (e.g., CYP3A4 — a liver enzyme that breaks down many drugs) do not meaningfully apply.

Historical Context & Evolution

Thylakoids themselves are not a designed drug; they are a naturally occurring plant structure, first characterized by botanists as the internal membranes of chloroplasts where the light-capturing reactions of photosynthesis occur. Their “original use” is therefore biological rather than medical.

The idea of using them for appetite control emerged from laboratory research at Lund University in Sweden in the mid-2000s. Investigating how biological membranes affect fat-digesting enzymes, Per-Åke Albertsson, Charlotte Erlanson-Albertsson, and colleagues reported in 2007 that chloroplast membranes retard fat digestion by inhibiting pancreatic lipase/colipase and, in doing so, induce satiety. This finding reframed a photosynthetic membrane as a potential food-based tool for reducing overeating, and led to a series of animal and human studies and to a commercial spinach-derived ingredient (Appethyl).

The actual early findings were consistent in direction: in mice, thylakoids raised CCK and reduced food intake and body weight; in healthy humans, they increased CCK and lowered insulin after a fatty meal. Over the following decade, the scientific reception evolved in two directions. Proponents extended the work to overweight women, reporting reduced hunger, fewer cravings, and greater weight loss. Independent scrutiny grew in parallel: reviewers noted that most trials were small, short, industry-linked, and conducted largely in women, and in 2023 the European Food Safety Authority (EFSA) evaluated an Appethyl weight-loss health claim and did not find the evidence sufficient to substantiate it. Rather than treating either the early enthusiasm or the regulatory skepticism as the final word, the current standing is best described as an intriguing, mechanistically plausible effect on satiety with unresolved questions about the magnitude and durability of any weight benefit.

Expected Benefits

Benefits below are framed for health- and longevity-oriented adults who are willing to time a supplement around meals and combine it with dietary effort, rather than as population-wide outcomes.

High 🟩 🟩 🟩

Increased Satiety and Reduced Hunger

Thylakoids taken before a meal increase feelings of fullness and reduce subjective hunger in the hours afterward, the best-supported effect in the literature. The proposed mechanism is delayed fat digestion driving release of the fullness hormones CCK and GLP-1 and suppression of ghrelin. This is supported by acute crossover RCTs and by a 2025 dose-response meta-analysis of randomized trials that found a significant increase in fullness ratings, though most contributing trials were small and several were conducted by the developers.

Magnitude: In controlled trials, thylakoids raised fullness ratings and lowered subjective hunger by roughly 20% over the 2–3 hours following a meal; the 2025 meta-analysis confirmed a statistically significant increase in fullness.

Medium 🟩 🟩

Body Weight and Body Fat Reduction ⚠️ Conflicted

Daily thylakoid supplementation alongside a balanced or calorie-reduced diet has been associated with greater loss of body weight and body fat than placebo in several 3-month RCTs in overweight women. Proposed mechanisms are reduced overall energy intake via enhanced satiety plus a small reduction in fat absorption. The evidence is directly conflicted: a flagship trial reported markedly greater weight loss with thylakoids, yet other short trials showed no significant weight difference, and the European Food Safety Authority judged the overall evidence insufficient to support a weight-loss claim. Discrepancies likely reflect small sample sizes, short duration, female-only populations, differing diets, and developer involvement.

Magnitude: Up to roughly 5 kg of body-weight loss over 3 months in one RCT (about 43% more than placebo), but not consistently replicated and judged insufficient by EFSA.

Reduced Cravings for Palatable Food

Thylakoids appear to reduce “hedonic hunger” — the urge to eat sweet, salty, or fatty foods for pleasure rather than need — which is relevant for adults trying to control snacking. The proposed basis is the same satiety-hormone shift plus altered reward signaling. Support comes from 3-month RCTs in overweight women reporting reduced urges for chocolate and sweets, with the usual caveats of small size and industry linkage.

Magnitude: Reduced the urge for palatable and sweet foods by roughly a third (self-reported) in 3-month RCTs in overweight women.

Low 🟩

Improved Post-Meal Blood Glucose and Insulin Response

Thylakoids may blunt the rise in blood glucose and insulin after a meal, of interest for metabolic health and longevity. The mechanism is slowed gastric emptying and delayed carbohydrate and fat absorption. Evidence includes small human oral glucose tolerance test (OGTT — a standard test of blood sugar handling) studies and animal work in pigs and rats, but human data are limited and effect sizes are not well established.

Magnitude: Not quantified in available studies.

Modest Improvement in Blood Lipids

Some trials report small reductions in LDL cholesterol (low-density lipoprotein — the “bad” cholesterol that raises cardiovascular risk), particularly when thylakoids are combined with diet or exercise. The proposed mechanism combines reduced fat absorption with weight and dietary changes. Evidence is limited to a few small studies, including exercise-combination trials in men with obesity.

Magnitude: Modest reductions in LDL cholesterol (single-digit percentage) reported in one 3-month RCT.

Speculative 🟨

Antioxidant and Anti-Inflammatory Support for Longevity

Thylakoid membranes are rich in chlorophyll, lutein, and other carotenoid pigments with antioxidant capacity, raising the possibility of anti-inflammatory or cellular-protective benefits relevant to aging. This is based on the pigment content and in-vitro and animal signals rather than controlled human longevity outcomes; no trial has tested thylakoids for lifespan or aging endpoints, so the basis is mechanistic and anecdotal only.

Favorable Shift in Gut Microbiota

Animal studies suggest thylakoids may alter the gut bacterial community in potentially beneficial ways, which could indirectly affect metabolism and inflammation. This remains speculative because the evidence is limited to rodents and has not been demonstrated for meaningful health outcomes in humans; the basis is mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No specific gene variants are established to modify thylakoid benefits. In principle, variants affecting lipase activity, CCK/GLP-1 signaling, or fat metabolism could influence response, but this has not been studied and remains theoretical.

  • Baseline biomarker levels: Individuals with higher baseline hunger, greater habitual craving for palatable foods, or elevated post-meal glucose may have more room to benefit, since the effect is on appetite and fat/carbohydrate handling. Those already highly satiety-responsive may notice little change.

  • Sex-based differences: Nearly all positive weight and craving trials were conducted in women, so efficacy is best documented in females. Emerging work in men (combined with exercise) suggests metabolic benefits, but direct sex comparisons are lacking, and it is unclear whether appetite effects are as strong in men.

  • Pre-existing health conditions: People with obesity, prediabetes, or polycystic ovary syndrome (PCOS — a common hormonal and metabolic condition in women) have been the main studied groups and may see metabolic benefits; those without excess weight or dysregulated appetite have not been studied and may benefit less.

  • Age-related considerations: Trials centered on middle-aged adults. Older adults with reduced appetite are at theoretical risk of unwanted appetite suppression and reduced intake, so any benefit in appetite control must be weighed against maintaining adequate nutrition at the older end of the target range.

Potential Risks & Side Effects

Risks below are framed for the risk-aware adult considering regular use, not for a general population.

High 🟥 🟥 🟥

Mild Gastrointestinal Effects

The most consistently reported side effects are mild digestive symptoms — loose stools, softer stools, flatulence, and bloating — arising because some dietary fat reaches the lower gut undigested. These are generally transient and are notably milder than those caused by the fat-blocking drug orlistat, because thylakoids only delay rather than prevent fat digestion. Across the human trials, tolerability was good and symptoms were the main, minor complaint.

Magnitude: Mild and transient; reported in a minority of participants and less severe than with orlistat, tending to increase with higher-fat meals.

Medium 🟥 🟥

Reduced Absorption of Dietary Fat and Fat-Soluble Nutrients

Because thylakoids slow fat digestion, a portion of dietary fat — and potentially some fat-soluble vitamins (A, D, E, K) and carotenoids carried with it — may be less completely absorbed, especially with regular use around fatty meals. The clinical relevance appears small because absorption is delayed rather than blocked, but long-term human data on fat-soluble vitamin status are lacking. This mechanism is the same one that produces the intended satiety effect.

Magnitude: Fat digestion is delayed, not blocked; net fat and nutrient malabsorption is small and far less than with orlistat.

Low 🟥

Vitamin K–Related Anticoagulant Interference

Spinach-derived thylakoid products can carry meaningful amounts of vitamin K (a nutrient that promotes blood clotting), which may reduce the effectiveness of vitamin K–antagonist blood thinners such as warfarin and destabilize INR (international normalized ratio — a standard measure of blood-clotting time). The relevance is confined to people on these specific anticoagulants; for others it is not a concern.

Magnitude: Not quantified in available studies.

Oxalate Load and Kidney Stone Risk

Spinach is high in oxalate (a compound that can contribute to calcium-oxalate kidney stones), so spinach-derived extracts may add to oxalate intake in susceptible individuals, particularly those with a history of stones. Purified thylakoid membrane preparations may contain less oxalate than whole spinach, but oxalate content is not always disclosed.

Magnitude: Not quantified in available studies.

Speculative 🟨

Unknown Long-Term Effects of Chronic Use

Because trials rarely exceed 3 months, the long-term consequences of daily thylakoid use — including any cumulative effect on fat-soluble vitamin status, bone health, or the gut lining — are unknown. This concern is based on the mechanism and the absence of long-term data rather than on reported harm.

Risk-Modifying Factors

  • Genetic polymorphisms: No specific variants are established to raise thylakoid-related risk. Individuals with inherited disorders of fat absorption or fat-soluble vitamin handling could theoretically be more vulnerable to malabsorption effects, but this is unstudied.

  • Baseline biomarker levels: Those with already-low fat-soluble vitamin status (e.g., low vitamin D) or borderline coagulation control may be more affected by any reduction in fat absorption or by added vitamin K, respectively.

  • Sex-based differences: Safety data are drawn mostly from women. No sex-specific safety signals have been identified, but tolerability and nutrient effects in men over the long term are less well characterized.

  • Pre-existing health conditions: People with a history of calcium-oxalate kidney stones, malabsorption syndromes, gallbladder or pancreatic disease, or those on anticoagulants face the greatest theoretical risk and warrant extra caution.

  • Age-related considerations: Older adults are more likely to be on anticoagulants and more susceptible to unintended appetite suppression and nutrient shortfalls, so risks are somewhat higher at the older end of the target range.

Key Interactions & Contraindications

  • Prescription drug interactions: Vitamin K–antagonist anticoagulants (warfarin) — the vitamin K in spinach-derived products may antagonize the drug and lower INR. Fat-soluble prescription medications and drugs dependent on dietary fat for absorption could theoretically have altered absorption when taken with a fatty meal plus thylakoids. Antidiabetic drugs (insulin, sulfonylureas such as glipizide) — additive lowering of post-meal glucose may increase hypoglycemia risk.

  • Over-the-counter medication interactions: Orlistat (alli) — a fat-blocking OTC weight-loss drug; combined use compounds fat malabsorption and gastrointestinal side effects and is not advised. OTC fat-soluble vitamin products may be less well absorbed if taken at the same time as a thylakoid-containing meal.

  • Supplement interactions: Fat-soluble vitamin supplements (A, D, E, K) and carotenoids (lutein, astaxanthin) — absorption may be reduced if co-ingested with thylakoids at a fatty meal; separate timing is prudent. Fish oil and other oil-based supplements may likewise be better absorbed if taken apart from the thylakoid dose.

  • Supplements with additive effects: Other appetite- or glucose-modulating supplements — viscous fibers (glucomannan, psyllium), berberine, and GLP-1-supporting agents — may have additive satiety or glucose-lowering effects; this can be desirable but warrants attention to avoid excessive appetite suppression or hypoglycemia when stacked.

  • Other intervention interactions: Combined with structured exercise and calorie restriction, thylakoids have shown additive metabolic benefits in small trials; combined with GLP-1 receptor agonist medications (e.g., semaglutide), additive appetite suppression is plausible but untested and could reduce intake excessively.

  • Populations who should avoid it: Pregnant and breastfeeding women (no safety data), children, people with active eating disorders, individuals with a history of calcium-oxalate kidney stones or fat-malabsorption disorders, and anyone on warfarin without INR monitoring should avoid or use only under medical supervision.

  • Severity and clinical consequence: Warfarin interaction — caution/monitor; consequence is reduced anticoagulation and potential clot risk. Antidiabetic combination — caution; consequence is hypoglycemia. Orlistat combination — avoid; consequence is pronounced fat malabsorption and gastrointestinal upset. Eating disorders and pregnancy — treat as contraindications given appetite suppression and absent safety data.

  • Mitigating actions: For warfarin users, keep vitamin K intake consistent and monitor INR more frequently if starting. For antidiabetic users, monitor blood glucose and adjust medication with a clinician. Separate fat-soluble vitamins and oil-based supplements from the thylakoid dose by several hours.

  • Population thresholds: Avoid in pregnancy and lactation (no data), in children (<18 years), and in recurrent calcium-oxalate stone formers; use only with monitoring in patients on vitamin K–antagonist anticoagulation (target INR typically 2–3) or on insulin/sulfonylureas.

Risk Mitigation Strategies

  • Start with a single daily dose before one meal: Beginning with about 5 g of thylakoid powder before a single meal (often breakfast or lunch), rather than before every meal, limits gastrointestinal symptoms such as loose stools and flatulence while gauging tolerance.

  • Take fat-soluble vitamins and oil-based supplements separately: Separating vitamins A, D, E, K, carotenoids, and fish oil from the thylakoid dose by at least 3–4 hours reduces the risk of impaired absorption caused by delayed fat digestion.

  • Keep vitamin K intake consistent and monitor INR on anticoagulants: For anyone on warfarin, maintaining steady dietary and supplemental vitamin K and checking INR more frequently when starting mitigates the risk of destabilized anticoagulation and clot formation.

  • Monitor blood glucose when combined with glucose-lowering therapy: Those on insulin or sulfonylureas should check blood glucose regularly and coordinate dose adjustments with a clinician to prevent hypoglycemia from additive post-meal glucose lowering.

  • Choose lower-oxalate or purified preparations if stone-prone: Individuals with a history of calcium-oxalate kidney stones can reduce oxalate exposure by selecting purified thylakoid membrane preparations with disclosed oxalate content, maintaining good hydration, and ensuring adequate dietary calcium.

  • Reassess fat-soluble vitamin status with prolonged use: For use beyond a few months, periodic checking of vitamin D and, where relevant, other fat-soluble vitamins guards against the theoretical cumulative malabsorption from chronically delayed fat digestion.

Therapeutic Protocol

  • Standard dose and form: Leading protocols, as used in the published trials, employ roughly 5 g of standardized spinach-derived thylakoid powder (e.g., the Appethyl ingredient), typically mixed into water, a smoothie, or yogurt and consumed shortly before a meal.

  • Competing approaches: Two main approaches exist without one being clearly established as default — a single pre-meal dose per day (most human weight and craving trials, from the Lund University group) versus dosing before multiple meals or pairing with structured exercise and calorie restriction (as in the exercise-combination trials in men with obesity). A whole-food alternative — consuming a large serving of blended green leaves — has been proposed but is less standardized.

  • Popularizing experts and clinics: The single pre-meal Appethyl protocol was developed and popularized by Charlotte Erlanson-Albertsson and Per-Åke Albertsson at Lund University; the exercise-combination protocols come chiefly from more recent groups studying men with obesity.

  • Best time of day: Dosing before a meal that contains some fat is standard, since fat is required for the lipase-delaying mechanism; breakfast or lunch is most commonly used so that appetite suppression covers the daytime hours when snacking is frequent.

  • Half-life: As a non-absorbed biological membrane acting in the gut lumen, thylakoids have no meaningful systemic half-life; their action is limited to the digestion window of the meal they are taken with, which is why pre-meal timing matters.

  • Single vs. split dosing: Trials generally used a single pre-meal dose rather than split dosing; because the effect is tied to an individual meal, some users take it before more than one meal, but evidence for multi-dose regimens is limited.

  • Genetic polymorphisms: No pharmacogenetic variants are established to guide thylakoid dosing; unlike drug interventions, there is no dose adjustment based on variants such as APOE4 (a gene affecting fat and cholesterol handling), MTHFR (a gene affecting folate processing), or COMT (a gene affecting breakdown of dopamine and stress signaling), as the compound is not systemically metabolized.

  • Sex-based differences: Efficacy for appetite and weight is best documented in women; men have mainly been studied in exercise-combination settings. There is no established sex-specific dose, but response expectations should account for this evidence imbalance.

  • Age-related considerations: No age-specific dosing is defined; older adults should be cautious about appetite suppression compromising adequate intake, favoring a single lower-impact daily dose.

  • Baseline biomarker levels: Those with higher baseline hunger, cravings, or post-meal glucose excursions may be better candidates; baseline weight, glucose, and lipid values help define whether a metabolic benefit is plausible and trackable.

  • Pre-existing health conditions: People with obesity, prediabetes, or PCOS are the best-studied responders; those on anticoagulants or with malabsorption or stone history should adjust the approach or avoid it, as noted in the interactions section.

Discontinuation & Cycling

  • Lifelong vs. short-term use: Thylakoids are best understood as a short- to medium-term appetite-support tool used alongside dietary change; no evidence supports indefinite lifelong use, and trials rarely extended beyond 3 months.

  • Withdrawal effects: No physical withdrawal syndrome is expected because thylakoids are not absorbed or habit-forming; on stopping, the appetite-suppressing and craving-reducing effects simply fade, and prior hunger patterns may return.

  • Tapering: No tapering protocol is needed; the supplement can be stopped abruptly without physiological consequence, though appetite may rebound to baseline.

  • Cycling: There is no established evidence that cycling improves or maintains efficacy; some users take it intermittently (e.g., during periods of active weight management) rather than continuously, but this is a practical preference, not an evidence-based regimen.

  • Practical framing: Because any weight benefit appears to depend on continued dietary effort, discontinuation without established eating habits risks regain; the supplement is a support to behavior change rather than a standalone or permanent fix.

Sourcing and Quality

  • Standardized ingredient: The most-studied source is the Appethyl branded spinach thylakoid ingredient (Greenleaf Medical AB); products built on a standardized, characterized thylakoid ingredient are preferable to generic “spinach extract” of undefined thylakoid content.

  • What to look for: Seek products that disclose thylakoid content and dose per serving, are produced under good manufacturing practice (GMP), and carry third-party testing for identity, heavy metals, and contaminants; spinach can accumulate heavy metals and nitrates, so contaminant testing matters.

  • Formulation and processing: Because thylakoid function depends on intact membranes, gentle drying and minimal heat/light exposure during processing help preserve activity; heavily processed or heat-degraded powders may be less effective.

  • Reputable options: Established supplement brands that use the Appethyl ingredient, or spinach leaf extract products from manufacturers with transparent sourcing and testing, are the more reliable choices; oxalate and vitamin K content disclosure is a plus for at-risk users.

  • Whole-food alternative: For those who prefer food over supplements, large servings of raw or lightly blended green leaves supply thylakoids naturally, though the delivered dose is far less concentrated and less standardized than a purpose-made extract.

Practical Considerations

  • Time to effect: Appetite and fullness effects can be felt acutely, within the first meal or two after dosing; craving and weight changes reported in trials accrued over several weeks to 3 months of daily use.

  • Common pitfalls: Expecting weight loss without dietary effort, taking the dose with a fat-free meal (which undercuts the lipase-based mechanism), co-timing it with fat-soluble vitamins, and using generic spinach powders of unknown thylakoid content are the most frequent mistakes.

  • Regulatory status: Thylakoid products are sold as dietary supplements, not approved drugs; in the European Union, a specific Appethyl weight-loss health claim was not authorized after EFSA review, so marketing weight-loss benefits is constrained there.

  • Cost and accessibility: Thylakoid supplements are moderately priced and available online and in some retail supplement channels; they are neither exceptionally expensive nor hard to obtain, though standardized branded-ingredient products cost more than generic spinach powders.

  • Realistic expectations: The most defensible expected outcome is modestly improved fullness and reduced snacking as an aid to a dietary program, rather than substantial standalone weight loss.

Interaction with Foundational Habits

  • Sleep: The interaction is indirect and largely neutral; thylakoids are not stimulants and are not known to disrupt or improve sleep directly. Any indirect benefit would come from reduced late-day snacking and better appetite regulation, which can support more consistent eating patterns; there are no timing concerns for sleep.

  • Nutrition: The interaction is direct and central. Thylakoids require a fat-containing meal to work, so they pair best with balanced meals that include some dietary fat; they may modestly reduce absorption of fat-soluble vitamins and carotenoids taken at the same meal, so nutrient-dense foods and separated supplement timing are advisable. They are a complement to, not a substitute for, a whole-food dietary pattern.

  • Exercise: The interaction is indirect and potentiating. In small trials, combining thylakoids with high-intensity functional or resistance training improved lipid and metabolic markers more than training alone, suggesting an additive effect; there is no evidence that thylakoids blunt training adaptations, and no specific timing around workouts is required beyond pre-meal dosing.

  • Stress management: The interaction is indirect. By reducing hedonic hunger and cravings, thylakoids may help blunt stress- and reward-driven eating, which can support stress-related dietary control; there is no evidence of a direct effect on cortisol or the physiological stress response.

Monitoring Protocol & Defining Success

Baseline testing before starting helps establish whether a metabolic or weight benefit is plausible and gives reference values to track. Recommended baseline measures include body weight and waist circumference, fasting glucose and HbA1c (hemoglobin A1c — a marker of average blood sugar over about three months), fasting insulin, a lipid panel, and — for anyone on anticoagulants — INR and vitamin K considerations.

Ongoing monitoring cadence: reassess weight, waist circumference, and subjective appetite/cravings at about 4 weeks and 12 weeks; recheck glucose, insulin, and lipids at roughly 3 months, then every 6–12 months with continued use; for anticoagulant users starting thylakoids, check INR more frequently (e.g., within 1–2 weeks) until stable.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Body weight / waist circumference Waist <94 cm (men), <80 cm (women) Tracks the primary intended outcome Waist reflects visceral fat better than weight alone; measure fasting, same time of day
Fasting glucose 70–85 mg/dL Gauges baseline and change in glucose handling Conventional “normal” extends to 99 mg/dL; functional target is tighter; requires 8–12 h fast
HbA1c <5.4% Reflects average glucose over ~3 months Conventional threshold for concern is 5.7%; useful for slow trends, not acute effects
Fasting insulin <6 µIU/mL Detects insulin resistance the intended metabolic effect may improve Conventional labs often flag only >25 µIU/mL; functional target is much lower; fast required
LDL cholesterol <100 mg/dL (lower if higher risk) Tracks the modest lipid changes reported in trials Best paired with ApoB (apolipoprotein B — a count of cholesterol-carrying particles) and triglycerides; fasting preferred; interpret with overall risk
Triglycerides <80 mg/dL Sensitive to dietary fat handling and metabolic change Conventional cutoff is 150 mg/dL; requires 8–12 h fast; sensitive to recent alcohol/carbohydrate
INR (if on warfarin) Individualized (commonly 2.0–3.0) Detects vitamin K–driven destabilization of anticoagulation Only relevant for vitamin K–antagonist users; check more often when starting
Vitamin D (25-OH) 40–60 ng/mL Screens for the theoretical fat-soluble vitamin malabsorption with long-term use Best checked at baseline and after several months of continuous use

Qualitative markers to track alongside labs:

  • Hunger and fullness: Whether meals feel more satisfying and hunger between meals is reduced.
  • Cravings: Reduced urge for sweets, snacks, and palatable foods, especially in the afternoon and evening.
  • Energy and eating patterns: Steadier daytime energy and fewer episodes of impulsive or reward-driven eating.
  • Digestive comfort: Absence of bothersome loose stools, bloating, or flatulence at the chosen dose.

Emerging Research

Emerging work is framed for the individual considering use, highlighting both studies that could strengthen and studies that could weaken the case for thylakoids.

  • Registered metabolic trials (completed): Two registered trials examined thylakoids for metabolic endpoints — NCT02702245 (“Effects of Two Doses of Thylakoids on OGTT,” ~21 participants, glucose intolerance) and NCT02687295 (“Improvement of Metabolic Health After Thylakoid Supplementation,” ~20 participants, metabolic syndrome/obesity), both sponsored by Region Skåne. As of the creation date, no large ongoing recruiting trials of thylakoids for weight or metabolic health were identified on ClinicalTrials.gov.

  • Exercise-combination research (could strengthen the case): Recent RCTs pairing spinach-derived thylakoids with high-intensity training in men with obesity reported added improvements in adipokines, insulin resistance, and lipids (Saeidi et al., 2023; Saeidi et al., 2024). These extend the evidence beyond women and beyond appetite alone, and could support a broader metabolic role if replicated independently.

  • PCOS and gut–brain research (could strengthen the case): Trials in women with polycystic ovary syndrome combined thylakoids with calorie restriction and reported changes in body composition and gut–brain and oxidative-stress markers (Pourteymour Fard Tabrizi et al., 2021; Nikrad et al., 2023). They suggest possible benefits in a specific metabolic population, though sample sizes remain small.

  • Independent replication and long-term durability (could weaken the case): The most important open question is whether the appetite and weight effects hold up in larger, longer, independently funded trials, given that the 2023 EFSA review found the existing evidence insufficient and most positive studies are developer-linked. Future adequately powered trials could either confirm a modest real effect or show that it does not translate into durable weight loss.

  • Fat-soluble nutrient safety (could weaken the case): No study has adequately assessed whether chronic use meaningfully impairs fat-soluble vitamin status; long-term data here could reveal a safety consideration not evident in short trials.

Conclusion

Thylakoids are the green membranes from inside plant cells, concentrated mostly from spinach into a powder taken before meals. Their appeal rests on a plausible idea: by slowing fat digestion, they prompt the gut to release fullness signals and quiet hunger, which may curb overeating and cravings. The strongest and most consistent finding is that they increase fullness and reduce hunger in the hours after a meal. Evidence for actual weight and body-fat loss is weaker and conflicting — one prominent study showed a clear benefit, others showed none, and a European regulatory review concluded the case was not yet made.

The evidence base has real limitations. Most trials were small, short, conducted largely in women, and — importantly — carried out or funded by the scientists who developed and commercialized the product, which is a clear conflict of interest that colors the headline claims. Side effects appear minor, mainly mild digestive changes, though long-term safety is untested. Taken together, thylakoids look like a low-risk, food-derived aid that may help take the edge off appetite and cravings as part of a broader effort to eat well, rather than a proven standalone tool for lasting weight loss. Where the evidence is thin or mixed, that uncertainty remains a defining feature of the overall picture.

Top - Benefits - Risks - Protocol